Physician profile
Toby E Margolin
NPI 1487270583
$1,385.14
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $551 · 2022: $567 · 2023: $243 · 2024: $23.96.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $267.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $267.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $503.08 | 2021-2024 | |
| Novo Nordisk INC | $134.51 | 2021-2022 | |
| Lilly USA, LLC | $118.99 | 2021-2022 | |
| Amarin Pharma, INC. | $106.32 | 2021-2022 | |
| Glaxosmithkline, LLC. | $102.09 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $101.18 | 2022-2023 | |
| Dexcom, INC. | $77.64 | 2021-2022 | |
| Antares Pharma, INC. | $47.31 | 2022 | |
| Jazz Pharmaceuticals INC. | $39.76 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $25.00 | 2022 | |
| Cmp Pharma, INC. | $20.62 | 2022 | |
| Amgen INC. | $18.55 | 2022 | |
| Pfizer INC. | $17.94 | 2021 | |
| Abbott Laboratories | $16.19 | 2022 | |
| Bausch Health US, LLC | $15.30 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascend Therapeutics US, LLC | $14.68 | 2021 | |
| Merck Sharp & Dohme LLC | $13.55 | 2021 | |
| Esperion Therapeutics, INC. | $12.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Toby Margolin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.